← All countries · Europe
95%
MCV1
2025 · WHO/UNICEF estimate
92%
DTP3
2025 · WHO/UNICEF estimate
92%
IPV complete
2025 · WHO/UNICEF estimate
1
Measles cases
2025 reported
545
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 98%2006 · WHO/UNICEF estimate | — | D · poor | |
| DTP1First dose of diphtheria-tetanus-pertussis | 98%2025 · WHO/UNICEF estimate | 98% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 92%2025 · WHO/UNICEF estimate | 92% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 98%2025 · WHO/UNICEF estimate | 98% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 92%2025 · WHO/UNICEF estimate | 92% | C · weak | |
| MCV1First dose of measles-containing vaccine | 95%2025 · WHO/UNICEF estimate | 95% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 92%2025 · WHO/UNICEF estimate | 92% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 95%2025 · WHO/UNICEF estimate | 95% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| HepB birthHepatitis B birth dose within 24 hours | —% · Administrative (country-reported) | — | too few points | no data |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 92%2025 · WHO/UNICEF estimate | 92% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 96%2025 · Administrative (country-reported) | 96% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 91%2025 · WHO/UNICEF estimate | 91% | A · strong | |
| RotaCRotavirus vaccine, complete series | 86%2025 · WHO/UNICEF estimate | 86% | A · strong | |
| Yellow feverYellow fever vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 80%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 65%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 74%2025 · WHO/UNICEF estimate | — | D · poor |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 12025 | 0.2per 1,000,000 total population | A · strong | |
| Rubella all countries · vaccine evidence | 12025 | 0.2per 1,000,000 total population | A · strong | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 22025 | 0.4per 1,000,000 total population | A · strong | |
| Pertussis (whooping cough) all countries · vaccine evidence | 5452025 | 96.9per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Tetanus (total) all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02021 | 0per 1,000,000 total population | D · poor | |
| Invasive meningococcal disease all countries · vaccine evidence | 192025 | 3.4per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 142025 | 2.5per 1,000,000 total population | B · good |
National schedule (latest WHO listing)
Show the schedule (44 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | <Y7 | Risk group(s) | Children <7 yrs at high risk of tuberculosis |
| COVID19COVID-19 vaccine | 1 | Adults | All adults, all older adults | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTAPDTaP (acellular) vaccine | 1 | Pregnant women | pregnant women | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 1 | M3 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 2 | M5 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 3 | M12 | General/routine | |
| DTAPIPVDTaP-IPV (acellular) vaccine | 4 | Y4 | General/routine | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Risk group(s) | Specified risk groups | |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | Risk group(s) | Specified risk groups. Children travelling to or staying in countries with intermediate or high hepatitis A endemicity Children with increased risk of exposure through household or close contacts Children in specific outbreak or exposure situations Children requiring combined hepatitis A and B vaccination due to overlapping risk factors | |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | Risk group(s) | Specified risk groups | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | Risk group(s) | Specified risk groups. Infants born to HBsAg-positive mothers - Infants in high-risk groups (e.g. born to an HBsAg-positive mother) are vaccinated immediately after birth (within the first day). Other at-risk children start the series as early as possible in infancy. The standard schedule is 0, 1, and 6 months. If the risk is identified later, vaccination can be started at any age without delay - Children with household exposure to hepatitis B virus Children born to parents from countries with intermediate or high hepatitis B endemicity Children in specific exposure settings (e.g. daycare with a known HBV-positive child) | |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 1 | <Y19 | Catch-up children | The HPV vaccine is offered free of charge in the national immunization programme to all children aged 10–12 (grades 5–6). The interval between the first and second dose will be at least 6 months. Catch-up for all boys and girls under 19 years of age. |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 1 | Y10-Y12 | HPV administered to females and males | The HPV vaccine is offered free of charge in the national immunization programme to all children aged 10–12 (grades 5–6). The interval between the first and second dose will be at least 6 months. Catch-up for all boys and girls under 19 years of age. |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 2 | +M6 | HPV administered to females and males | The HPV vaccine is offered free of charge in the national immunization programme to all children aged 10–12 (grades 5–6). The interval between the first and second dose will be at least 6 months. Catch-up for all boys and girls under 19 years of age. |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y65 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M6-Y6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | Risk group(s) | Children with chronic conditions | |
| IPVIPV (Inactivated polio vaccine) | 1 | Travellers | Booster if travelling at endemic country for longer than 4 weeks or arriving from such a country and previous booster over 12 months ago | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | Risk group(s) | Specified risk groups. The meningococcal ACWY vaccine is provided free of charge as part of the national immunisation programme to individuals who have an increased risk of severe meningococcal infection due to their medical condition or medication. The risk groups defined by THL include individuals with: complement deficiency treatment with complement-inhibiting medication absence of the spleen impaired splenic function, including those with sickle cell disease chronic graft-versus-host disease following a stem cell transplant. | |
| MEN_BMeningococcal B vaccine | 1 | Risk group(s) | Specified risk groups. Meningococcal B vaccine is provided free of charge as part of the national immunisation programme to individuals who, due to their illness or medication, have an increased risk of severe meningococcal infection. According to THL, the risk groups include individuals with: complement deficiency treatment that inhibits complement activation absence of the spleen (asplenia) impaired splenic function, including individuals with sickle cell disease chronic graft-versus-host disease following stem cell transplantation | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 2 | Y6 | General/routine | Second dose is administered if child already has protection against varicella |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | Y6 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | M3 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 2 | M5 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 3 | M12 | General/routine | |
| PCV13PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine | 1 | Risk group(s) | Specified risk groups | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | <Y5 | Risk group(s) | For children <5 years at high risk of severe pneumococcal disease, and after stem cell transfusion |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M3 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M5 | General/routine | |
| TBE_ADULTAdult TBE (tick borne encephalitis) vaccine | 1 | >=Y3 | Adults · SUBNATIONAL | In specified risk areas |
| TBE_PEDIATRICPediatric TBE (tick borne encephalitis) vaccine | 1 | >=Y3 | General/routine · SUBNATIONAL | In specified risk areas |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 5 | Y14-Y15 | General/routine | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 6 | Y25 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | Y45 | Adults | Boosters at Y45, Y65, and >65 years every 10th year |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | Y65 | Adults | Boosters at Y45, Y65, and >65 years every 10th year |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | Y75 | Adults | Boosters at Y45, Y65, and >65 years every 10th year |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 4 | Y85 | Adults | Boosters at Y45, Y65, and >65 years every 10th year |
| VARICELLAVaricella vaccine | 1 | M18 | General/routine |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.